Using Bedside Spectral Doppler Ultrasound for the Assessment of Patients With Thyrotoxicosis
Authors' conclusion
SDUS can be a valuable, efficient, and cost-effective bedside tool in the initial assessment of patients presenting with thyrotoxicosis.
Study context
- Population
- Patients diagnosed with thyrotoxicosis at an academic outpatient endocrinology clinic, August 2019 to November 2022; mean age 45.2 ± 16.4 years, 74.0% female
- Participants
- 73 patients
- Outcome
- Accuracy of SDUS initial assessment diagnosis
- Follow-up
- Initial encounter
Methodological detailssingle academic outpatient endocrinology clinic
- Single academic outpatient endocrinology clinic
Main finding
As reported in the abstract
Spectral Doppler Ultrasound (SDUS)
89.0%
65 events
- Conclusive and confirmatory at initial encounter before additional testing
- 55 (75.3%)
Observational data: associations, not effects.
Further findings
Confirmed diagnoses
- GD
- 48 (65.8%)
- Thyroiditis
- 13 (17.8%)
- Toxic adenoma
- 4 (5.5%)
- Amiodarone-induced thyroiditis type 2
- 4 (5.5%)
- Toxic multinodular goiter
- 1 (1.4%)
- Unremarkable repeat thyroid function testing
- 1 (1.4%)
- Unconfirmed
- 2 (2.7%)
Thyroid scan obtained
- Thyroid scan obtained
- 9 (12.3%)
Incorrect diagnoses by category
- Incorrectly diagnosed in each of GD, thyroiditis, toxic adenoma and unconfirmed diagnoses
- 2 patients each
Original publication
Using Bedside Spectral Doppler Ultrasound for the Assessment of Patients With Thyrotoxicosis. Endocr Pract. Published 7 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →